Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB626-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TRANCE/TNFSF11/RANK L Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from ascites. Detects human TRANCE/TNFSF11/RANK L in direct ELISAs. No cross-reactivity with recombinant mouse TRANCE is observed.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
O14788
- Isotype
- IgG
- Antibody clone number
- 70525
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts.
A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies.
Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier JP, Martel-Pelletier J, Boileau C
Bone 2009 Jun;44(6):1143-50
Bone 2009 Jun;44(6):1143-50
A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies.
Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, Daw NC, Prockop DJ, Horwitz EM, Gregory CA
British journal of cancer 2007 Dec 3;97(11):1552-9
British journal of cancer 2007 Dec 3;97(11):1552-9
Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI
Arthritis and rheumatism 2006 May;54(5):1463-72
Arthritis and rheumatism 2006 May;54(5):1463-72
Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.
Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhão H, Resende C, Castelão W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M
Clinical and experimental rheumatology 2005 Mar-Apr;23(2):185-92
Clinical and experimental rheumatology 2005 Mar-Apr;23(2):185-92
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Mandelin J, Li TF, Hukkanen M, Liljeström M, Salo J, Santavirta S, Konttinen YT
The Journal of rheumatology 2005 Apr;32(4):713-20
The Journal of rheumatology 2005 Apr;32(4):713-20
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- TRANCE/TNFSF11/RANK L in Human Lymph Node. TRANCE/TNFSF11/RANK L was detected in immersion fixed paraffin-embedded sections of human lymph node using 5 µg/mL Mouse Anti-Human TRANCE/TNFSF11/RANK L Monoclonal Antibody (Catalog # MAB626) overnight at 4 °C. Tissue was stained with the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Osteoclast-Like Cell Formation Induced by TRANCE/TNFSF11/RANK L and Neutralization by Human TRANCE/TNFSF11/RANK L Antibody. In the presence of Recombinant Mouse M-CSF (20 ng/mL, Catalog # 416-ML), Recombinant Human TRANCE/TNFSF11/RANK L (Catalog # 390-TN) induces osteoclast-like cell formation in RAW 264.7 mouse macrophages in a dose-dependent manner (orange line), as measured by TRAP (tartrate-resistant acid phosphatase) activity in cell lysates. Under these conditions, osteoclast-like cell formation elicited by Recombinant Human TRANCE/ TNFSF11/RANK L (30 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human TRANCE/TNFSF11/RANK L Monoclonal Antibody (Catalog # MAB626). The ND50 is typically 0.8-2.5 µg/mL.